SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (152)4/16/1997 1:37:00 PM
From: David Richardson   of 305
 
Yes. I have not met Marr yet, but I assume he is going to steer this ship in the right direction.

Let's face it, IMUL has also been unlucky. Who could of known that Marion Merrow Dow would have been bought out by a bunch of Germans (Hoechst), and that another bunch of Germans, i.e. (Schering) would sell 1,000,000 shares of IMUL because they had doubled their money in one year and had better uses for it. Wall Street overreacted to both of these events.

Those events coupled with the FDA insisting on another round of clinical trials and changes in management have brought the stock price to its present value of ~ 4.00/share.

I do know 2 things : the allervax peptides work because the molecular biology behind them is scientifically sound (although not fully understood) and the current stock price is a bargain and I added to my position last week.

Best regards
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News